Search

Displaying results 1251 - 1260 of 6198 in total
  1. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    of illnesses caused by other protozoa or helminths [A31976]. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment

  2. Drug

    Icodextrin

    go.drugbank.com/drugs/DB00702
    ApprovedInvestigational

    Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers.

    Mixtures: EXTRANEAL CON ICODEXTRIN AL 7.5%
  3. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.

  4. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

  5. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. … [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019.

  6. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]

    Categories: MATE 2-K Inhibitors
  7. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … [A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes.

  8. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

  9. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.

  10. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    The defribrinogenation of blood results in an anticoagulant effect. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.